Mach7 Technologies Limited (M7T) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the Mark 7 First Half FY26 Result Briefing. My name is Françoise Deberlac and I'm Head of Investor Relations for Mark 7. Today our CEO Terry Thomas and our CFO Daniel Lee will provide an overview of the first half result. We will then open it up for questions. If you have a question, please submit it via the Q&A text box at the bottom of the screen. I'll now hand over to Terri. Thank you, Francoise. And hello, everybody, and thank you for joining us for the first half fiscal year 2026 results. Let me start with something that I think we can all align on. Sales matters. Sales fuels growth. It funds innovation, and innovation fuels more growth. And ultimately, sales drives shareholder value. Now, I happen to love sales. I've spent more time in sales than any other role in my career, and I believe it makes the business world go round. But more importantly, I know that sustainable, disciplined sales growth is what you want to see from Mach 7, and I do too. Good news is we now have an enhanced, growing, and focused team driving progress. strengthening pipeline quality, improving conversion discipline, and aligning our commercial engine with our strategy. You'll hear more about that shortly, including a guest appearance later in the presentation. So let's begin. On our vision, before getting into performance, I really want to ground us into who Mach 7 is and where we're going. Our vision is simple, but it's ambitious to be the global imaging EMR. We win by completing the patient picture with the patient's pictures, and we do it better than anyone else. Healthcare has done a strong job organizing text-based and numerical clinical data, but imaging remains fragmented. It's locked in silos across departments, different formats, and that fragmentation creates fricti...